0001209191-20-005034.txt : 20200127 0001209191-20-005034.hdr.sgml : 20200127 20200127171503 ACCESSION NUMBER: 0001209191-20-005034 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200123 FILED AS OF DATE: 20200127 DATE AS OF CHANGE: 20200127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Paul Robert CENTRAL INDEX KEY: 0001757964 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38792 FILM NUMBER: 20550624 MAIL ADDRESS: STREET 1: C/O ALECTOR, INC. STREET 2: 151 OYSTER POINT BLVD., #300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Alector, Inc. CENTRAL INDEX KEY: 0001653087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462702363 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD., SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-231-5660 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD., SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Alector LLC DATE OF NAME CHANGE: 20150915 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-23 0 0001653087 Alector, Inc. ALEC 0001757964 Paul Robert C/O ALECTOR, INC. 131 OYSTER POINT BLVD, SUITE 600 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock 2020-01-23 4 M 0 6000 8.16 A 279719 D Common Stock 2020-01-23 4 S 0 5401 24.22 D 274318 D Common Stock 2020-01-23 4 S 0 599 25.22 D 273719 D Stock Option (right to buy) 8.16 2020-01-23 4 M 0 6000 0.00 D 2028-07-01 Common Stock 6000 338000 D The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.00 to $24.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $25.21 to $25.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. One forty-eighth (1/48th) of the shares subject to the option vested on August 2, 2018, and an additional one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. /s/ Stephanie Yonker, attorney-in-fact 2020-01-27